Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clemastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 14/20 | 0.84 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.84 |
| ▸ | HTR1A | P08908 | 2/20 | 0.84 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.84 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.84 |
| ▸ | DRD1 | P21728 | 2/20 | 0.84 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.84 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.84 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.84 |
| ▸ | DRD3 | P35462 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clemastine SCHEMBL18787212 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MEN1GMNNLMNA | |
| Clemastine SCHEMBL27597691 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MEN1GMNNLMNA | |
| Clemastine SCHEMBL28170352 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MEN1GMNNLMNA | |
| Clemastine SCHEMBL4098555 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MEN1GMNNLMNA | |
| Clemastine SCHEMBL33403 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MEN1GMNNLMNA | |
| Clemastine SCHEMBL15526489 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MEN1GMNNLMNA | |
| Clemastine SCHEMBL3017168 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MEN1GMNNLMNA | |
| Clemastine SCHEMBL4102782 | 0.94 | CYP3A4 (0.89) | CYP3A4SMN1; SMN2MEN1GMNNLMNA | |
| Clemastine SCHEMBL23785540 | 0.92 | CHRM3 (1.00) | CYP3A4SMN1; SMN2MEN1GMNNLMNA | |
| Clemastine SCHEMBL4087919 | 0.92 | CHRM3 (1.00) | CYP3A4SMN1; SMN2MEN1GMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7638 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| WO-2025100462-A1 | SOLID COMPOSITION CONTAINING BROMHEXINE | 第一三共ヘルスケア株式会社 | 2025-05-15 | — | — | WO | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| CN-119409612-A | Resolution refining method of clemastine fumarate | 南京斯泰尔医药科技有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-119185192-A | Chloromastine fumarate injection and preparation method thereof | 南京斯泰尔医药科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-118851971-A | Efficient synthesis method of clemastine fumarate | 南京斯泰尔医药科技有限公司 | 2024-10-29 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-12064407-B2 | Endogenous retrovirus-k (ERVK) encodes an alternate envelope protein | UNIVERSITY OF WINNIPEG (CA) | 2024-08-20 | — | — | US | claimed |
| US-20240074944-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2024-03-07 | — | — | US | claimed |
| EP-0652774-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER. | PROCTER & GAMBLE (US) | 1995-05-17 | — | — | EP | claimed |
| EP-0608320-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| EP-0582380-A1 | Dry granulation using a fluidized bed | McNEIL-PPC, INC. (US) | 1994-02-09 | — | — | EP | claimed |
| WO-1994002176-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | THE PROCTER & GAMBLE COMPANY (US) | 1994-02-03 | — | — | WO | claimed |
| US-5273758-A | Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms | SANDOZ LTD. (CH) | 1993-12-28 | — | — | US | claimed |
| WO-1993007902-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |
| EP-0316345-A1 | LIPOSOMES WITH ENHANCED RETENTION ON MUCOSAL TISSUE | LIPOSOME TECHNOLOGY, INC. (US) | 1989-05-24 | — | — | EP | claimed |
| EP-0316345-A4 | LIPOSOMES WITH ENHANCED RETENTION ON MUCOSAL TISSUE. | LIPOSOME TECHNOLOGY INC (US) | 1989-05-16 | — | — | EP | claimed |
| WO-1988000824-A1 | LIPOSOMES WITH ENHANCED RETENTION ON MUCOSAL TISSUE | LIPOSOME TECHNOLOGY, INC. (US) | 1988-02-11 | — | — | WO | claimed |